Rethinking Clinical Trials

JANUARY 31, 2024

DIHI approaches this work through four pillars of innovation: implementation and health delivery science, health technology innovation, leadership and workforce development, and best practices development and dissemination. The Health AI Partnership started with 7 organization partners and has expanded to about 20 organizations.

Production 164

Production Development Clinical Trials Clinical Trials 164

Rethinking Clinical Trials

AUGUST 18, 2022

for Health Equity and Inclusive Excellence. Because the system and structures have not been built equitability, we will need to invest more and have more transparency and accountability at every level, from the investigator, funder, publisher and journals. There are barriers at the health care professional and researcher level.

Clinical Trials 130

Clinical Trials Clinical Trials Trials Insulin 130

Rethinking Clinical Trials

NOVEMBER 16, 2022

Berman Institute of Bioethics & Johns Hopkins Bloomberg School of Public Health. clinicians, health systems), data may have been collective for administrative/clinical purposes, data may be more representative of “real world” conditions, and data may be controlled by a third party (e.g. Stephanie Morain, PhD, MPH.

Clinical Trials 246

Clinical Trials Clinical Trials Trials Research 246

Rethinking Clinical Trials

JANUARY 17, 2024

The COVID Therapeutics Committee worked with the state health department to develop a policy for fair allocation of scarce medications to treat COVID-19. Tags #pctGR, @Collaboratory1 The post Grand Rounds January 12, 2024: Design and Implementation of a Weighted Lottery to Equitably Allocate Scarce Covid-19 Resources (Erin K.

Clinical Trials 173

Clinical Trials Clinical Trials Antibody Trials 173

The Pharma Data

NOVEMBER 29, 2021

1.1.529 a variant of concern, named Omicron, on the advice of WHO’s Technical Advisory Group on Virus Evolution (TAG-VE). WHO’s TAG-VE will continue to monitor and evaluate the data as it becomes available and assess how mutations in Omicron alter the behaviour of the virus. Recommended actions for countries.

Vaccination 52

Vaccination Vaccine Genome Genomics 52

pharmaphorum

JANUARY 21, 2022

“Access to medicines remains one of the most challenging policy areas in every country we work with through the pan-European region,” said Natasha Muscat, Director of Country Health Policies and Systems at World Health Organization (WHO) Europe. WHO is OMI? The current situation, said Muscat, is “unacceptable”.

Medicine 52

Medicine Marketing Manufacturing Production 52

Drug Discovery World

MAY 22, 2023

But are these price tags a barrier to access? Biotech and pharma are actively working with payers and insurers to deliver on equitable pricing models that ensure access. The cost 2022 has not been shy of approvals – Uniqure and CSL’s Haemophilia B drug even nabbed the title of “Most Expensive Drug” at $3.5 million per dose.

Gene Therapy 52

Gene Therapy Gene Drugs Contamination 52